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of key parameters. CONCLUSION: Clopidogrel as an
alternative to ASA is a cost-effective strategy in secondary
prevention of ischemic events for high-risk atherothrom-
botic patients.
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OBJECTIVES: Fondaparinux, a new synthetic selective
factor XA inhibitor was recently introduced into the
market. This may have widespread implications for
Health care providers that are expected to vary across
countries. We evaluated the cost-effectiveness of fonda-
parinux relative to enoxaparin up to 5-years in the pre-
vention of venous thromboembolism (VTE) following
major orthopaedic surgery and compared the results
across European countries. METHODS: We developed
an economic model and assessed the effect of fonda-
parinux relative to enoxaparin , both given for 7 days, on
patient clinical outcomes and costs in Belgium, Italy, The
Netherlands, Spain, UK. The perspective was that of 
the third party payer. Outcomes are symptomatic deep
vein thrombosis, pulmonary embolism, recurrences, post-
thrombotic syndrome and death. Data on the incidence
of VTE events were derived from four randomised clini-
cal trials comparing enoxaparin with fondaparinux, and
from a review of the literature. Resource consequences
and costs were estimated locally using national or hospi-
tal databases, clinician opinion, literature . . . and vali-
dated by experts. RESULTS: In a hypothetical cohort 
of 1000 patients, weighted to reﬂect the proportion of
patients undergoing hip or knee replacement, or hip frac-
ture surgery in each country, the expected number of VTE
events averted with fondaparinux ranged from 17 to 20
and the number of VTE-related deaths averted is 2 to 3.
Results were consistent across countries: break-even point
in costs was achieved at day 90 or even earlier. The
expected savings with fondaparinux at 5 years would
range between €26,000 and €38,000. These ﬁndings were
found to be robust to wide variations in key assumptions
in the model. CONCLUSIONS: Compared with current
practice in Europe, fondaparinux is a cost-effective and
dominant strategy in the prophylaxis of venous throm-
boembolism following major orthopaedic surgery in all
countries investigated.
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Drug-eluting stents (DES) have been shown to reduce the
risk of restenosis post coronary intervention compared
with conventional stents (CS). However, the cost of DES
is signiﬁcantly higher than CS. OBJECTIVE: To evaluate
the utilization of DES along with clinical indications, out-
comes and cost impact within the cardiac catheterization
lab. METHODS: Demographic, clinical and angiographic
data were collected retrospectively on all patients who
underwent DES implantation between October 15, 2002
and April 15, 2003. Cost data, speciﬁcally stent costs,
were collected concurrently. RESULTS: A cohort of 46
patients was treated with DES, involving 52 vessels and
utilizing 62 stents (56 Cypher, 6 Taxus). Indications for
coronary intervention were stable angina (67.2%) and
ACS/post MI (32.6%). Indications for DES use included
clinical reasons such as diabetes mellitus (15.2%), prior
bypass surgery (19.6%) and renal insufﬁciency (8.7%).
Angiographic indications included: stenosis length 
>18mm (43.4%), vessel diameter <2.5mm (32.6%),
patients with multivessel disease (21.7%) and instent
restenosis (8.7%). Short-term clinical complications
included death but no strokes or myocardial infarctions.
The procedural success was 95.8% (44/46), and the clin-
ical success was 92.5% (43/46). The average number of
DES per patient was 1.35. During the same time period,
351 patients were treated with CS, utilizing 522 stents.
The average number of stents per patient was 1.48. The
total hospital-incurred DES cost was $227,500 for an
average stent cost $4945.65 per patient. In the CS group
the total cost for stents was $496,050 for an average cost
of $1413.25 per patient. The average stent cost per
patient was 3.5 times higher in the DES group than with
CS. CONCLUSIONS: 1) Indications for DES use are con-
sistent with individuals at higher risk for restenosis; 2) the
procedural costs for treating these individuals are signif-
icantly greater; and 3) full 6 month outcomes and cost
data will be available for presentation.
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OBJECTIVE: The aim of the study was to investigate
gender differences in persistence with antihypertensive
drugs (AHT). METHODS: Data for this study were
obtained from the PHARMO system including pharmacy
records and hospitalisations in the Netherlands (n =
950,000). Patients between 1997–2001 who newly
received monotherapy of AHTs were selected. One-year
persistence was deﬁned as the percentage of patients using
AHTs at least 270 days and receiving AHT in 3 months
after the 1-year follow-up period. Persistence was pre-
sented as 1-year persistence (95% CI). Odds ratios (OR)
were calculated with logistic regression and adjusted for
age, use of antidiabetics and lipid lowering drugs, and
prior cardiovascular hospitalizations. RESULTS: In the
period 1997–2001, 17,113 patients newly received at
least one AHT prescription with a follow-up >15 months.
Of these patients, random samples of 500 patients per
drug class were drawn. Persistence was highest in
angiotensin II receptor blockers (ARBs) (62.1%), pro-
gressively lower in ACE-inhibitors (60.2%), betablockers
(35.5%), calcium channel blockers (34.7%), and diuret-
ics (33.0%), resulting in the highest OR of 3.3 [95% CI:
2.5–4.4] for ARBs compared to diuretics. The persistence
of AHT use in women is substantially lower than in men
(40.4% versus 50.3%, OR 0.7 [95% CI: 0.6–0.8]). CON-
CLUSIONS: These results demonstrate marked differ-
ences in persistence between AHT classes, with the
highest persistence for ARBs and lowest for diuretics.
Women were less persistent with their AHT compared to
men. This low persistence leads to suboptimal treatment
with substantial consequences. Especially in women,
more improvement can be gained to improve their car-
diovascular outcome.
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OBJECTIVES: In a previous study, we have identiﬁed side
effects and lack of drug insurance coverage as the deter-
minants of discontinuation in a group of patients newly
prescribed antihypertensive medications. The current
study aimed at identifying the determinants of non adher-
ence to medication among those who had not discontin-
ued. METHODS: We conducted a prospective cohort
study in which individuals prescribed a new antihyper-
tensive monotherapy were identiﬁed through a network
of 173 pharmacies. We interviewed participants by tele-
phone three times over a 3-month period. At the end of
this period, those individuals which reported still taking
the medication initially prescribed, were included in the
analysis. Self-reported non adherence was measured at
three month using the Morisky’s 4-item questionnaire.
Those answering yes to any one of the 4 questions were
deemed to be non adherent. We analyzed data using a
multivariable logistic regression model. RESULTS: Of
509 eligible participants, 118 (23.2%) reported non
adherence to their drug treatment. Non adherence was
signiﬁcantly associated with the use of angiotensine con-
verting enzyme inhibitors (Adjusted Odds Ratio (AOR) =
3.0; 95% Conﬁdence Interval (CI) 1.2–7.9) as compared
to angiotensin II antagonist losartan, and the belief that
hypertension is not a risk factor for cardiovascular dis-
eases (AOR = 2.0; 95% CI 1.2–3.3). On the other hand,
non adherence was inversely associated with the use of
more than 4 pills of medication a day (AOR = 0.3; 95%
CI 0.2–0.6). CONCLUSIONS: Our ﬁndings suggest that
determinants of non adherence are not the same as those
for discontinuation. They also suggest that adherence to
drug treatment could be improved by a proper selection
of medication, and by attempts to correct wrong percep-
tions patients may have about hypertension. Our ﬁnding
that taking more than four pills was associated with
better adherence is concordant with data recently pub-
lished by others.
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OBJECTIVES: To compare the discontinuation rates due
to poor tolerability in patients with overactive bladder
treated with either once daily dosed extended release
(XL), or twice or greater daily dosed, immediate release
(IR) oxybutynin. METHODS: We used the real-world
longitudinal data (1995–2002) from IMS Mediplus UK
to identify all patients new to therapy initiated on either
oxybutynin IR or XL. The ﬁrst script deﬁned the patients
study cohort and the date of that script was the study
index date from which monitoring outcomes followed.
These scripts were linked to reason to stop therapy,
including poor tolerability. The start-date-match ap-
proach was used to adjust for the later market entrance
of oxybutynin XL. We used c2 test to evaluate the statis-
tical signiﬁcance in the difference of discontinuation rates
between both groups. RESULTS: We identiﬁed 147
patients initiated on oxybutynin XL and 216 patients on
oxybutynin IR, with an average daily dose of 10.0mg and
8.9mg respectively. Patient demographics were compara-
ble. In the oxybutynin XL group, 29 patients (19.7%)
had a record for stopping therapy compared to 129
